.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,977,042

« Back to Dashboard
Patent 6,977,042 protects STRIVERDI RESPIMAT, SPIRIVA RESPIMAT, COMBIVENT RESPIMAT, and STIOLTO RESPIMAT, and is included in four NDAs.

This patent has fifty-one patent family members in thirty-five countries.

Summary for Patent: 6,977,042

Title: Microstructured filter
Abstract:A microstructured filter having an inlet for unfiltered fluid; an outlet for filtered fluid; a plurality of projections which are arranged in at least two rows in mutually juxtaposed relationship, project out of a base plate and are an integral component of the base plate; a plurality of passages between the projections and a cover plate which is securable to the base plate to cover the projections and the passages. The passages form a plurality of through paths from the inlet to the outlet. The inlet includes an elongate inlet slot for the unfiltered fluid that extends over approximately the entire filter width and is approximately as high as the projection on the outlet side of the filter.
Inventor(s): Kadel; Klaus (58458 Willen, DE), Geser; Johannes (55218 Ingelheim, DE), Eicher; Joachim (44227 Dortmund, DE), Freund; Bernhard (D-55435 Gau-Algesheim, DE), Dunne; Stephen Terence (Stownmarket, Suffolk IP14 3AE, GB), Bachtler; Wulf (D-55125 Mainz, DE)
Assignee:
Application Number:10/780,864
Patent Claim Types:
see list of patent claims
Process; Device;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 68th percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYes6,977,042► subscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015RXNo6,977,042► subscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-001Sep 24, 2014RXYes6,977,042► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,977,042

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 42 439Sep 26, 1997

Non-Orange Book Patents for Patent: 6,977,042

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,645,383Microstructured filter► subscribe
6,846,413 Microstructured filter► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,977,042

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina010946► subscribe
Austria228386► subscribe
Austria357956► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc